It has been shown in both non-tumor (293A-TOA) and cancer (HCT116) cells that TMG treatment induces intron retention in the OGT transcript to regulate OGT expression; the intron retention is responsive to changes in O-GlcNAc levels and is regulated by a conserved intronic splicing silencer [14]. Here, OGT is linked to neoplasm.